DFTXDefinium Therapeutics, Inc.
Medicinal Chemicals & Botanical Products
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$166M
- 60% YoY
- Market cap
- $4.9B
- Employees
- 105
- Net debt / EBITDA
- —
- −$619M net debt
- AI in 10-K
- 0.4
- mentions per 10K words
Takeover score 2 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo2% of assetsOver 40% of assets
- Shareholder dissentNo93% lowest supportAny vote under 80% support
Buyer economics 2 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AIYes0.4 per 10K words · 17th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$4.9B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$7M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$94M | −$66M | −$94M | −$104M | −$166M | 60% |
| Net income | −$93M | −$57M | −$96M | −$109M | −$184M | 69% |
| Operating cash flow | −$46M | −$50M | −$64M | −$79M | −$132M | 66% |
| Stock-based comp | $43M | $14M | $15M | $17M | $20M | 19% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $7M · 17
- Net
- −$7M
Pay vs performance
No pay-versus-performance disclosure yet.